transgene

A Clinical-Stage Biotech Company Harnessing the Power of MVA

June, 2026

Transgene is a biotechnology company recognized for its innovative *myvac*® platform, which develops Individualized Neoantigen Therapeutic Vaccines based on Modified Vaccinia Ankara (MVA) viral vector technology to stimulate the immune system against cancer. Building on its strong expertise in viral vector engineering, Transgene is also expanding its research into acute infectious diseases.

Novel Generation of Prophylactic MVA-based Mpox Vaccine

MVA-Cell-Line Manufacturing

Creating a modern, cost effective and scalable MVA-cell-line based platform

- Cell-line production
- Better efficacy
- Scalable manufacturing

myvac — Individualized Therapeutic Vaccine Platform

Transgene's lead asset and main value creation driver

TG-MVA — Novel prophylactic vaccine against smallpox & mpox

Opportunity to generate upside with limited risk
Scalable platform beyond *Orthopoxviruses*

TG-MVA | A New MVA-based Prophylactic Vaccine in the Fight Against Mpox and Available to Address Smallpox Biodefense Gaps

Loss of collective immunity

orthopox-naïve people
~450M in EU + US
<1B in Africa

Endemic & recurring

mpox is a structurally recurrent threat

Top-priority biosecurity

Smallpox
= Category A agent

Concentrated supply

One dominant supplier

Sources for EU/US: 1. US census bureau, population data 2. Eurostat population data; Sources for Africa: 3. UN-DESA URPAS population data; 4. WHO

transgene

transgene

A Clinical-Stage Biotech Company Harnessing the Power of MVA

June, 2026

MVA, an ideal platform for immunogenicity



- Non-replicating pox vaccine built on a viral backbone similar to reference platform
- Designed to protect against mpox, smallpox and more broadly *Orthopoxviruses*[1] infections
- 2-dose schedule enabling durable protection without boosters

Cost-Effective high-volume solution enabled by cell-line manufacturing



- Scalable
- Lower COGS enabled by cell-line production
- Freeze-dried/ lyophilized formulation enabling long-term stockpiling and easier transportation/storage
- Overcoming ethical and industrial limits of CEF[2] production

EU to start, US to expand



- Part of a broader European ecosystem, combining EU-based CDMO and CROs with public and institutional scientific collaborations
- Flexible EU approval based on epidemic context

LMIC[3]: Optimized for global access & high-need regions



- Stable, low-COGS product with flexible fill-finish for broad deployment
- Easily transferable manufacturing enabling regional production


1. Orthopoxvirus: a group of related viruses (Poxviridae family) including smallpox and monkeypox
2. CEF = chicken embryo fibroblast 3. LMIC = Low- and middle-income countries

transgene

transgene

A Clinical-Stage Biotech Company Harnessing the Power of MVA

TG-MVA | Preclinical Data Demonstrates Efficacy, Immunogenicity and Safety Comparable to Reference Vaccine Against Mpox



EFFICACY

Strong protection against lethal mpox

- **100% survival** in mice
- **7/8 survival** in non-human primates
- **Markedly reduced skin lesions** vs unvaccinated controls
- **Attenuated viral burden** in blood and throat

IMMUNOGENICITY

Broad humoral & cellular response

- **Neutralizing antibodies** vs VACV and MPXV (clades I & II)
- **Seroconversion in all** vaccinated animals (peak ~D42)
- **Detectable T-cell immunity** (ELISpot)
- **Comparable to reference vaccine** in magnitude and kinetics

SAFETY

Favorable and comparable profile

- **Comparable safety** to reference vaccine
- **Slight-to-mild, transient** local reactogenicity
- **Consistent** with the established MVA safety profile

TG-MVA manufacturing confirmed the MVA platform's feasibility with a scalable, consistent process and no impact on potency or safety

➢ **Next development steps** will be planned in alignment with Health Authorities

Contact:
Nathalie Bruck Bour | bruck@transgene.fr

transgene



transgene

Boulevard Gonthier d’Andernach
Parc d’Innovation
67405 Illkirch-Graffenstaden – France

www.transgene.com